MORE OPTIONS FOR MORE PATIENTS EVOLUT™ TAVI
THE FIRST AND ONLY TAVI platform
approved for treatment of patients
with severe BICUSPID aortic stenosis*
30-day outcomes in bicuspid
vs Tricuspid1 with Evolut™ platform
Strong clinical and procedure outcomes at 30 days for patients with bicuspid and tricuspid aortic valves.¹
EVOLUT™ TAVI LOW RISK INDICATION
Learn more
CLINICAL AND PROCEDURAL OUTCOMES
TOTAL AORTIC REGURGITATION
EVOLUT™ PRO
System
Transcatheter Aortic Valve Implantation (TAVI)
The EVOLUT™ platform offers patients with bicuspid aortic valve disease excellent hemodynamics.²
WHY EVOLUT™?
DESIGNED FOR EXCELLENT
PATIENT OUTCOMES
HEMODYNAMICS MATTER
The supra annular design of the EVOLUT™ TAVI platform allows for exceptional hemodynamics in challenging, bicuspid anatomies.3
Patients benefit from larger EOAs which decreases Patient Prosthesis Mismatch (PP M) and improves exercise capacity, helping them return to an active life.4-5
NUMERICALLY LOWER RATE OF
ANNULAR RUPTURE WITH EVOLUT™6
“The risk of aortic rupture or dissection is greater in patients with a bicuspid aortic valve than in the general population”7
EVOLUT™ is associated with a numerically lower rate of annular rupture in bicuspid patients compared to Sapien™3.6
PRECISE PLACEMENT
“The repositioning feature of EVOLUT™ platform is of particular utility in TAVI for bicuspid aortic stenosis.”8
Choose Evolut TAVI for a minimally invasive option to effectively treat the complexities of the heavily calcified, degenerative stenotic bicuspid anatomy.
References
1
Jeffrey J. Popma et al. Outcomes in Patients with Bicuspid Aortic Valve Disease with Evolut R Self-Expanding Transcatheter Aortic Valve Replacement: A Report From the United States STS/ACC TVT Registry™
2
John K. Forrest et al Self-Expanding Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Bicuspid Valve Morphology A Report from the Society of Thoracic Surgeons / American College of Cardiology Transcatheter Valve Therapy Registry™ CR T19
3
Philip F, Faza NN, Schoenhagen P, et al. Aortic annulus and root characteristics in severe aortic stenosis due to bicuspid aortic valve and tricuspid aortic valves: implications for transcatheter aortic valve therapies. Catheter Cardiovasc Interv 2015; 86:E88–98.
4
Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthetic aortic valve replacement. Heart. May 2008;94(5):637-641.
5
Van Slooten YJ, van Melle JP, Freling HG, et al. Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart. January 2016;102(2):107-113.
6
Mangieri_EuroPCR 2019_Balloon vs self expandable valve for treatment of bicuspid aortic valve stenosis the BEAT international collaborative registry
7
Sung-Han Yoon, MD, et al. Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid versus Tricuspid Aortic Valve Stenosis
8
De Biase Chiara BivolutX presented at PCR LV 2019
*Evolut™ TAVI Platform is indicated for treatment of patients with severe bicuspid aortic stenosis who are at intermediate or greater risk for SAVR.
See the CoreValve Evolut R and CoreValve Evolut PRO device manuals for detailed information regarding the instructions for use , indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.
The commercial name of the Evolut™ R device is Medtronic CoreValve™ Evolut™ R System, and the commercial name of the Evolut™ PRO device is Medtronic Corevalve™ Evolut PRO System
© 2020 Medtronic. All rights reserved, Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic™.* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.